China Shineway Pharmaceutical Group Limited
CSWYY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3,778,043 | $4,516,538 | $3,950,636 | $3,223,550 |
| % Growth | -16.4% | 14.3% | 22.6% | – |
| Cost of Goods Sold | $946,294 | $1,122,419 | $1,012,322 | $813,214 |
| Gross Profit | $2,831,749 | $3,394,119 | $2,938,314 | $2,410,336 |
| % Margin | 75% | 75.1% | 74.4% | 74.8% |
| R&D Expenses | $100,522 | $110,462 | $117,454 | $112,711 |
| G&A Expenses | $291,320 | $326,499 | $279,804 | $256,557 |
| SG&A Expenses | $1,888,625 | $2,308,122 | $2,107,284 | $1,763,260 |
| Sales & Mktg Exp. | $1,597,305 | $1,981,623 | $1,818,652 | $1,499,682 |
| Other Operating Expenses | $0 | $0 | -$104,980 | -$82,853 |
| Operating Expenses | $1,989,147 | $2,418,584 | $2,119,758 | $1,793,118 |
| Operating Income | $842,602 | $975,535 | $713,576 | $534,365 |
| % Margin | 22.3% | 21.6% | 18.1% | 16.6% |
| Other Income/Exp. Net | $303,119 | $264,718 | $203,449 | $185,738 |
| Pre-Tax Income | $1,145,721 | $1,240,253 | $917,025 | $720,103 |
| Tax Expense | $305,669 | $270,743 | $194,252 | $163,429 |
| Net Income | $840,052 | $969,510 | $722,773 | $556,674 |
| % Margin | 22.2% | 21.5% | 18.3% | 17.3% |
| EPS | 444 | 512.2 | 384 | 296 |
| % Growth | -13.3% | 33.4% | 29.7% | – |
| EPS Diluted | 444 | 513.4 | 384 | 296 |
| Weighted Avg Shares Out | 1,889 | 1,893 | 1,889 | 1,888 |
| Weighted Avg Shares Out Dil | 1,889 | 1,889 | 1,889 | 1,888 |
| Supplemental Information | – | – | – | – |
| Interest Income | $176,718 | $95,207 | $98,469 | $102,885 |
| Interest Expense | $6,129 | $2,737 | $630 | $1,254 |
| Depreciation & Amortization | $68,735 | $177,102 | $185,862 | $182,386 |
| EBITDA | $1,220,585 | $1,420,092 | $1,103,517 | $903,743 |
| % Margin | 32.3% | 31.4% | 27.9% | 28% |